Table 3.

Effect of NAC, amlodipine, lisinopril or allopurinol administration on markers of inflammation.

Parameters	Control groupA	Acetaminophen groupB	NAC treatment groupC	Amlodipine treatment groupD	Lisinopril treatment groupE	Allopurinol treatment groupF
Hepatic NOx (nmol/g)	123.5 ± 5.99	216.7 ± 7.05a	153.7 ± 9.43ab	174.4 ± 2.51ab	175.9 ± 3.63ab	168.8 ± 3.25ab
Hepatic MPO (U/g)	0.380 ± 0.0574	3.820 ± 0.3739a	0.574 ± 0.0779b	0.819 ± 0.1429b	0.790 ± 0.0929b	0.547 ± 0.1240b

Data are expressed as mean of 6–8 rats ± SEM. Multiple comparisons were done using one-way ANOVA test followed by Student–Newman-Keuls as post hoc test.

ANOVA: Analysis of variance, MPO: Myeloperoxidase, NAC: N-acetylcysteine, NOx: Total nitrate/nitrite, SEM: Standard error of the mean.

^AControl group receiving only vehicles.

^BAcetaminophen group, subjected to a single oral dose of acetaminophen (750 mg/kg).

^CTest agents were given orally on a daily basis for 14 consecutive days prior to acetaminophen dose, where NAC was given in a dose of 300 mg/kg/day.

^DTest agents were given orally on a daily basis for 14 consecutive days prior to acetaminophen dose, where amlodipine was given in a dose of 10 mg/kg/day.

^ETest agents were given orally on a daily basis for 14 consecutive days prior to acetaminophen dose, where lisinopril was given in a dose of 20 mg/kg/day.

^FTest agents were given orally on a daily basis for 14 consecutive days prior to acetaminophen dose, where allopurinol was given in a dose of 50 mg/kg/day.

^aSignificantly different from control group.

^bSignificantly different from acetaminophen group at p < 0.05.